Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 127

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 127
---
 to meet our existing liabilities and anticipated needs over the next twelve months from the date hereof. We will need
to raise additional capital to continue our operations and to implement our business plan, which capital is unlikely to be available on
favorable terms or at all. In addition, if we are able to raise sufficient capital and potentially license or acquire new technologies,
we expect our expenses to significantly increase if and when we are able to support preclinical models, product manufacturing, perform
preclinical studies, including toxicology studies, initiate clinical development, and eventually, if successful, seek marketing approval
for, any product candidates. Since the closing date of the Reverse Merger, our limited cash position has slowed our product development
and other activities to remain afloat. If we are unable to raise additional capital, we may be forced to cease our operations altogether.

If we are able to raise sufficient capital and potentially
license or acquire new technologies, our funding needs may fluctuate significantly based on several factors, including, but not limited
to:

·the scope, progress, results and costs of product
development and manufacture of drug product to support preclinical and clinical development of potential product candidates;

·the extent to which we enter into additional
collaboration arrangements regarding product discovery or development;

·the costs, timing and outcome of regulatory review
of product candidates;

·our ability to establish additional collaborations
with favorable terms, if at all;

·the costs of future commercialization activities,
including product sales, marketing, manufacturing and distribution, for any of product candidates for which we receive marketing approval;

·the costs of preparing, filing and prosecuting
patent applications, maintaining and enforcing any potential intellectual property rights and defending any potential intellectual property-related
claims;

·the costs to in-license technology for new products
or technologies; and

·revenue, if any, received from commercial sales
of product candidates, should any product candidates receive marketing approval.

Identifying potential product candidates and conducting
manufacturing and process development, preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that
takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product
sales. In addition, any product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be
derived from sales of products that we do not expect to be commercially available for several years, if at all. Accordingly, we will need
to continue to rely on additional financing